Twitter | Search | |
Search Refresh
SHARE Cancer Support Jul 19
Navigate your own pathology report with the help of Dr. Tamara Kalir, who will explain how to read one and clarify what goes in your report to help you better understand it all. Register with the link here today:
Reply Retweet Like
SGO Jul 18
Join SGO and Shannon Westin, MD, for a webinar 8/8 at 7 pm CT covering PARP inhibitor use in gyn oncology, including the history of use and supporting research, patient selection, common toxicities and toxicity management.
Reply Retweet Like
Tanya Temkin Jul 18
Study shows that although half of women treated for and experience significant fatigue, only 8% saw symptoms abate without intervention. Yet few receive interventions to lessen the fatigue. .
Reply Retweet Like
MD Anderson Cancer Center Jul 18
Congratulations on this well-deserved recognition, ! Thanks to you and for all you do to advance cancer research and care.
Reply Retweet Like
J.J. Wallbillich, MD 8h
Here's a advocacy mantra: every new case of locally advanced or metastatic should be considered a sentinel event for .
Reply Retweet Like
Emil Lou, MD, PhD Jul 19
Replying to @JAMAOnc
13/ Thank you to for publishing our work. Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer
Reply Retweet Like
Lawrence Kasherman Jul 20
We’ve had some pretty positive feedback from our latest patient information videos on managing bowel obstruction in gynecologic cancers!
Reply Retweet Like
Sabin Motwani Jul 18
Replying to @sabinbmotwanimd
Results: Superiority of VCB+C vs pelvic RT was not demonstrated. Acute toxicity greater w VCB+C; late toxicity was similar. Vaginal (2.5%) & distant recurrence rates (18%) similar between arms. Pelvic or PA nodal recurrences more common with VCB+C (9% v 4%).
Reply Retweet Like
Emil Lou, MD, PhD Jul 19
Replying to @cancerassassin1
12/ We hope these findings will be a starting point for examining utility of histologic assessment of tumor-stroma proportion as a straightforward biomarker, and also a launching point for further investigation of cellular and molecular mechanisms of chemoresistance.
Reply Retweet Like
Sarah Temkin 14h
How do women feel about the availability of population based testing? asked
Reply Retweet Like
National Cancer Institute Jul 13
Many women diagnosed with ovarian and breast cancers are not receiving tests for inherited genetic mutations:
Reply Retweet Like
OncLive SOSS 15h
Jubilee Brown, MD, of , discusses the importance of molecular testing immediately after an ovarian cancer diagnosis and how molecular testing will shape the field of ovarian cancer
Reply Retweet Like
Targeted Oncology 13h
Dr. Yadav talks through the results of a preclinical trial that found synergy in the combination of the PARP inhibitor and the pan-HER TKI neratinib for uterine serous cancers that overexpress HER2.
Reply Retweet Like
Emil Lou, MD, PhD Jul 19
Replying to @cancerassassin1
1/ Platinum-based therapy is the backbone of treatment of women with . Like most potentially invasive and aggressive cancers, ovarian cancer cells develop . This happens in 15-30% of cases of ovarian cancer.
Reply Retweet Like
Targeted Oncology Jul 20
Are you keeping up to date on the latest updates & approvals in the field of gynecologic oncology? Targeted Oncology covers the most up-to-date news in the field here:
Reply Retweet Like
Dee Sparacio Jul 20
SGO, Others Partner On Ovarian Cancer Quality Initiative“to launch a quality initiative to identify and provide guidance on issues related to the optimal care of patients with advanced epithelial ovarian cancer.”
Reply Retweet Like
Dee Sparacio Jul 18
Useful to see trials presented in this way. A bird’s-eye view of clinical trials provides new perspectives on drug research and development via
Reply Retweet Like
Emil Lou, MD, PhD Jul 20
Thanks very much, Dee! Assessment is very straightforward - and can be done using the slides already prepared by pathologists to make the initial diagnosis. If validated further, it could be a useful + inexpensive biomarker.
Reply Retweet Like
CU Cancer Center Jul 20
Check out what Saketh Guntupalli had to say about leadership vision and higher survival rates for gynecologic cancers!
Reply Retweet Like
Bionest Partners Jul 17
's Zejula racks up first-line maintenance win in even in non- patients. How will Zejula stand up to and 's Lynparza?
Reply Retweet Like